Full metadata record
DC FieldValueLanguage
dc.creatorHuarte, E. (Eduardo)-
dc.creatorCubillos-Ruiz, J.R. (Juan R.)-
dc.creatorNesbeth, Y.C. (Yolanda C.)-
dc.creatorScarlett, U.K. (Uciane K.)-
dc.creatorMartinez, D.G. (Diana G.)-
dc.creatorBuckanovich, R.J. (Ronald J.)-
dc.creatorBenencia, F. (Fabian)-
dc.creatorStan, R.V. (Radu V.)-
dc.creatorKeler, T. (Tibor)-
dc.creatorSarobe, P. (Pablo)-
dc.creatorSentman, C.L. (Charles L.)-
dc.creatorConejo-Garcia, J.R. (José R.)-
dc.identifier.citationHuarte E, Cubillos-Ruiz JR, Nesbeth YC, Scarlett UK, Martinez DG, Buckanovich RJ, et al. Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res 2008 Sep 15;68(18):7684-7691.es_ES
dc.description.abstractDendritic cells (DC) and cytokines that expand myeloid progenitors are widely used to treat cancer. Here, we show that CD11c(+)DEC205(+) DCs coexpressing alpha-smooth muscle actin and VE-cadherin home to perivascular areas in the ovarian cancer microenvironment and are required for the maintenance of tumor vasculature. Consequently, depletion of DCs in mice bearing established ovarian cancer by targeting different specific markers significantly delays tumor growth and enhances the effect of standard chemotherapies. Tumor growth restriction was associated with vascular apoptosis after DC ablation followed by necrosis, which triggered an antitumor immunogenic boost. Our findings provide a mechanistic rationale for selectively eliminating tumor-associated leukocytes to promote antitumor immunity while impeding tumor vascularization and to develop more effective DC vaccines based on a better understanding of the tumor microenvironment.es_ES
dc.publisherAmerican Association for Cancer Researches_ES
dc.subjectDendritic Cells/immunologyes_ES
dc.subjectOvarian Neoplasms/immunologyes_ES
dc.titleDepletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunityes_ES

Files in This Item:
There are no files associated with this item.

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.